Search

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

Meeting report | HOPE LA 2019 | Mendoza, Argentina

The first edition of the Highlights of Past EHA (HOPE) meeting in Latin America (LA) was held on October 4-5, 2019 in Mendoza, Argentina.

Read more

Turkey tutorial focused on lymphoma

The 8th EHA-TSH Hematology Tutorial was held on April 6-7, 2019 in Izmir, Turkey. This marks yet another pleasant and fruitful collaboration between EHA and the Turkish Society of Hematology.

Read more

EHA-SWG Scientific Meeting on Patient-centered Geriatric Hematology - report

Live sessions: October 6-7, 2021

Chairs: Prof R Cordoba (Spain) and Dr V Goede (Germany)

An international group of hematologists, specialist nurses, patient advocates, geriatricians, basic research, and pharma representatives gathered digitally to participate in this meeting.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more